Theradaptive — Department of Defense SBIR Phase I: DHA17-009
Theradaptive — SBIR Phase I award from Department of Defense.
- Amount
- $149,999
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase I
- Topic
- DHA17-009
- Solicitation
- 2017.1
- NAICS
- —
- Place of performance
- FL
- Period
- 2017-07-19 → 2018-02-18
Description
Our proposal develops an osteochondral repair platform that is conformable to a wide variety of injury geometries without the need for pre-operative customization. Further this platform does not rely on any autologous tissue and is amenable to scalable manufacturing methods. The basis of this platform is a targeted delivery technology that permits site-specific osteo-chondral induction within injury sites. The biologic carrier platform is able to deliver multiple osteoinductive and chondro-inductive biologics in a spatially controlled way that permits cartilage repair that is distal to bone repair. This allows the surgeon to mold the implant to any geometry and to control where bone and cartilage repair occur in a seamless manner that mimics natural articular cartilage integration into supporting bone.